Physician profile
Michelle Biddinger
NPI 1326015033
$4,217.02
in general payments reported to CMS, 2019-2025
20 companies · $846 in 2025
The $846 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $457 · 2021: $12.36 · 2022: $206 · 2023: $665 · 2024: $689 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $979.81 | 2019-2025 | |
| Novo Nordisk INC | $909.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $528.12 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $368.07 | 2019-2025 | |
| Astellas Pharma US INC | $332.39 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $262.47 | 2019-2023 | Arexvy |
| Pfizer INC. | $146.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.80 | 2019 | |
| Abbott Laboratories | $106.67 | 2025 | Freestyle Libre 3 |
| Evoke Pharma, INC. | $100.38 | 2025 | |
| Janssen Pharmaceuticals, INC | $91.94 | 2019 | |
| Merck Sharp & Dohme LLC | $82.34 | 2023 | Vaxneuvance |
| Amarin Pharma, INC. | $54.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.62 | 2019 | |
| Azurity Pharmaceuticals, INC. | $21.51 | 2025 | Edarbi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.47 | 2020 | |
| Surgenex LLC | $14.06 | 2025 | Surmatrix, Renograft, Ardeograft |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.78 | 2019 | |
| Dynavax Technologies Corporation | $12.69 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Biddinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.